ASRT
Assertio Holdings Inc
NASDAQ · Pharmaceuticals
$12.74
+1.12 (+9.64%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 51.42M | 46.50M | 50.98M |
| Net Income | 12.66M | 11.15M | 14.28M |
| EPS | — | — | — |
| Profit Margin | 24.6% | 24.0% | 28.0% |
| Rev Growth | -9.1% | +24.8% | -5.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 19.81M | 22.71M | 25.70M |
| Total Equity | 27.65M | 31.18M | 30.14M |
| D/E Ratio | 0.72 | 0.73 | 0.85 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 19.18M | 17.15M | 17.67M |
| Free Cash Flow | 16.80M | 10.93M | 11.61M |